|Description||Ruboxistaurin, also called as LY 333531, initially developed for the treatment of diabetic retinopathy, inhibits isolated enzymes PKCβI and PKCβII with a half-maximal inhibitory constant of 4.5 and 5.9 n M , respectively. The half-life of ruboxistaurin, which can be orally administered, is approximately 9 h and that of its metabolite 16 h, therefore allowing once-daily dosing. Based on data from clinicalTrials.gov, Children's Hospital Medical Center, Cincinnati plan a phase I/II trial of the effect of ruboxistaurin for its safety, tolerability, and effectiveness in treating adult patients with heart failure on June 9, 2016.|
|Brife Description||Protein kinase C beta inhibitor|
|Synonyms||13-((dimethylamino)methyl)-10,11,14,15-tetrahydro-4,9:16,21-dimetheno-1H,13H-dibenzo(e,k)pyrrolo(3,4-h)(1,4,13)oxadiazacyclohexadecene-1,3(2H)-dione; Arxxant; LY 333531; LY-333531; LY333531; ruboxistaurin; ruboxistaurin mesilate hydrate|
|Solubility||Soluble in DMSO|
|Storage||Store in a cool and dry place and at 0 - 4℃ for short term (days to weeks) or -42℃ for long term (months to years).|
|Shelf Life||2 years|
|Boiling Point||744.4ºC at 760mmHg|
|Current Developer||Eli Lilly; Takeda; Children's Hospital Medical Center and The Christ Hospital|
Bryostatin 3 has been found to be a potent protein kinase C activator and could probably be useful in studies of emerging cancers.
The Pharmacological activity of this molecular is Growth Inhibition of Malignant<br/>Cells in vivo and in vitro and cytotoxic properties may result inhibition<b...
Ruboxistaurin, also called as LY 333531, initially developed for the treatment of diabetic retinopathy, inhibits isolated enzymes PKCβI and PKCβII with a half-m...
Zoledronic acid monohydrate
Zoledronic acid (zoledronate) is a bisphosphonate bone resorption inhibitor, an inhibitor of farnesyl diphosphate (FPP) synthase which results in downstream inh...
PKC ζ pseudosubstrate, a synthetic peptide, is an inhibitor of protein kinase C (PKC) ζ that attached to cell permeabilisation Antennapedia domain vector peptid...
TAS-301 is a potent and selective constrictive remodeling regulator on renarrowing after balloon overstretch injury of porcine coronary artery. TAS-103 inhibits...
Midostaurin is a multi-target protein kinase inhibitor being investigated for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
PKC (19-36) is a pseudosubstrate peptide inhibitor of protein kinase C (IC50 = 0.18 μM).